Emily K. Bergsland
Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.
Overview
Emily Bergsland is Professor of Medicine and Associate Director for Education at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist focused on gastroenteropancreatic neuroendocrine tumours, she chaired the Alliance A021202 trial of pazopanib versus placebo in progressive carcinoid tumours and co-authors national neuroendocrine tumour treatment guidelines. Her papers include NCCN guidance on the management of advanced gastroenteropancreatic neuroendocrine tumours, a review of systemic therapies for advanced gastrointestinal carcinoid tumours and the A021202 trial report. Her record links to lutetium-177 dotatate, somatostatin receptor 2 and VEGF-directed therapy, and she leads UCSF's cancer education programmes.
| Title | Journal | Year |
|---|---|---|
| Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors | Journal of the National Comprehensive Cancer Network | 2025 |
| Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors | Hematology/Oncology Clinics of North America | 2016 |
| Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (Alliance A021202) | Journal of Clinical Oncology (ASCO Annual Meeting abstract) | 2019 |
Similar pages
not linked directly; found by shared links- PersonSimron Singh
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonJonathan R. Strosberg
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PersonRahul Aggarwal
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters), Lutetium-177.
- InstitutionErasmus MC Cancer Institute
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- CompanyMolecular Targeting Technologies
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Lutetium-177.
- InstitutionUppsala University Hospital / Uppsala University
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Neuroendocrine tumours, Radioligand therapy (beta emitters).